The Diabetic Macular Edema Market Size is valued at USD 3.95 billion in 2023 and is predicted to reach USD 4.56 billion by the year 2031 at a 1.9% CAGR during the forecast period for 2024-2031.
Diabetic Macular Edema (DME) is an ocular disorder associated with diabetes, characterized by fluid accumulation in the macula, resulting in swelling and impaired central vision. If untreated, it may result in visual loss; however, therapy alternatives exist to mitigate swelling and protect sight.
Hence, the adoption of Diabetic Macular Edema is expected to increase in the near future as concerns grow over diabetic patients. Growing risk factors such as aflibercept, bevacizumab, and ranibizumab are factors expected to drive the growth of the global Diabetic Macular Edema market. The investment in the healthcare sector is another factor expected to augment the target market growth. The increasing research and development activities globally are expected to boost market expansion in the coming years.
Although the COVID-19 pandemic and the high cost of treating diabetic macular edema could limit the target market's growth during the forecast period, rising R&D activities, government policies to use sustainable components for production, and investments by major players are all anticipated to create lucrative growth opportunities in the revenue for players operating in the global market for diabetic macular edema over the forecast period.
Competitive Landscape
Some Major Key Players In The Diabetic Macular Edema Market:
- Novartis AG
- Bayer AG
- Allergen Plc.
- Hoffmann-La Roche Ltd.
- Alimera Sciences Inc.
- Valeant Pharmaceuticals International, Inc.
- KalVista Pharmaceuticals
- Genentech
- Oxurion
- Ocugen, Inc
- Regeneron Pharmaceuticals, Inc.
- Clearside Biomedical
- Daiichi Sankyo
- Arctic Vision
- Chugai Pharmaceutical Co., Ltd.
- Sanofi
- Novartis AG
- Sun Pharmaceutical Industries Ltd.
- Aurobindo Pharma
- Lupin
- Allergan
- Merck & Co., Inc.
- Pfizer Inc.
- GlaxoSmithKline plc
- IRIDEX Corporation
- Other Market Players
Market Segmentation:
The Diabetic Macular Edema market is segmented based on drug type, form, and distribution channel. The drug types are anti-VEGF, Corticosteroid therapies, and others. By form, the market is segmented into intravitreal injections and intravitreal implants. The distribution channel segment includes hospitals, speciality clinics, and mail-order pharmacies.
Based On Drug Type, The Anti-VEGF Segment Is Accounted As A Major Contributor In The Diabetic Macular Edema Market.
The anti-VEGF category is expected to hold a major share of the global Diabetic Macular Edema market in 2023. This is attributed to the growing usage of these drugs due to their work by the selective reserve of vascular endothelial growth factor. Additionally, the latest anti-VEGF drug formulations have offered improved efficacy and treatment intervals.
The Intravitreal Injections Segment Witnessed Growth At A Rapid Rate.
The intravitreal injections segment is projected to grow at a rapid rate in the global Diabetic Macular Edema market owing to growing concerns for the treatment of diabetic macular edema. Hence, with the growing cases of diabetic patients and the safety and tolerability of intravitreal injections, there is an increase in demand for Diabetic Macular Edema in the healthcare.
In The Region, The North American Diabetic Macular Edema Market Holds A Significant Revenue Share.
In the near future, the North American Diabetic Macular Edema market is likely to have the biggest revenue share of the market. This can be attributed to the strong focus on diabetic patients' health in the region, with the increasing adoption of Diabetic Macular Edema to cure the eye disease. In addition, the drug industry in the region is focusing on the production of Diabetic Macular Edema to develop sustainable and environmentally friendly solutions. Moreover, the presence of sophisticated photocoagulation laser manufacturers in the region is a factor in increasing the growth of the target market. In addition, Europe is projected to to see rapid growth in the global diabetic macular edema market due to growing concerns about diabetic patients, rising drug expenditure, government initiatives, and increasing funding in various industries.
Diabetic Macular Edema Market Report Scope
|
Report Attribute |
Specifications |
|
Market Size Value In 2023 |
USD 3.95 Bn |
|
Revenue Forecast In 2031 |
USD 4.56 Bn |
|
Growth Rate CAGR |
CAGR of 1.9% from 2024 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Million and CAGR from 2024 to 2031 |
|
Historic Year |
2019 to 2023 |
|
Forecast Year |
2024-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
Drug Type, Form, And Distribution Channel |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South East Asia; South Korea |
|
Competitive Landscape |
Novartis AG, Bayer AG, Allergan Plc, F. Hoffmann-La Roche Ltd., Alimera Sciences Inc., Valeant Pharmaceuticals International, Inc., KalVista Pharmaceuticals, Genentech, Oxurion, Ocugen, Inc., Regeneron Pharmaceuticals, Inc., Clearside Biomedical, Daiichi Sankyo, Arctic Vision, Chugai Pharmaceutical Co., Ltd. And Other market players |
|
Customization Scope |
Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
info@insightaceanalytic.com
